Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* A person who has been diagnosed with acute coronary syndrome (ACS) and is to undergo a percutaneous coronary intervention (PCI)~* A person who is of East or Southeast Asian descent~* A person who is of the legal age of 18 (or age 21 in Singapore) and is mentally competent to provide a signed written informed consent before entering the study~* If a woman is of childbearing potential, she must test negative for pregnancy and agree to use a reliable method of birth control~Exclusion Criteria:~* A person who has a severe cardiovascular condition such as cardiogenic shock at the time of randomization, ventricular arrhythmias or congestive heart failure~* A person who is at an increased risk of bleeding (e.g. active internal bleeding, history of bleeding disorder, recent fibrinolytic therapy before randomization into the study)~* A person who has prior history of any one of the following: ischemic or hemorrhagic stroke; intracranial neoplasm, arteriovenous malformation, or aneurysm; prior history of transient ischemic attack (TIA)~* A person who needs to take other antiplatelet therapy other than Aspirin for the duration of the study~* A person who receives daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX2) inhibitors that cannot be discontinued~* A person who has a severe liver disease, such as cirrhosis~* A person who has a condition such as alcoholism, mental illness, or drug dependence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prasugrel 60/10 Primary (Type: EXPERIMENTAL): Loading dose 60 mg followed by maintenance dose 10 mg/day
- Prasugrel 30/7.5 Primary (Type: EXPERIMENTAL): Loading dose 30 mg followed by maintenance dose 7.5 mg/day
- Prasugrel 30/5 Primary (Type: EXPERIMENTAL): Loading dose 30 mg followed by maintenance dose 5 mg/day
- Clopidogrel 300/75 Primary (Type: ACTIVE_COMPARATOR): Loading dose 300 mg followed by maintenance dose 75 mg/day
- Prasugrel 30/5 Low Weight/Elderly (Type: EXPERIMENTAL): Loading dose 30 mg followed by maintenance dose 5 mg/day
- Clopidogrel 300/75 Low Weight/Elderly (Type: ACTIVE_COMPARATOR): Loading dose 300 mg followed by maintenance dose 75 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).